ABOUT TNA

Founded in 2021 by respected experts who wanted to share their passion about bringing medical cures to those most in need. We are developing best-in-class small molecules with the ultimate aim to provide significant patient benefit.

ABOUT TNA THERAPEUTICS

Developing Potential Treatments for a Variety of Tumor Types

TNA Therapeutics Inc. is clinical stage pharmaceutical company focused on developing TNAT-101, a safe and well-tolerated first in class, oral agent that inhibits BCL3.

By reducing and in most cased preventing further metastasis This improves the ability of the immune system to fight cancer, making tumours more susceptible to a broad range of oncology treatments. TNAT-101 has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments.

We will be completing IND required studies in order to file an IND and begin clinical trials to evaluate TNAT-101 in monotherapy and in combination with checkpoint inhibitors and targeted therapies in solid and haematological malignancies as it advances towards a registration study in colorectal cancer and metastatic breast cancer.

THE FUTURE

Partnering, Collaborating & Combining Towards
the Future

TNA Therapeutics will grow through partnerships and collaborations, including:

Grants received such as the Alderley Park/CRUK/UK Innovate award recently provided to the company
Co-development agreements where we intend to further evaluate checkpoint inhibitors in combination with TNAT-101 in CRC and TNBC.
Combination studies in both CRC and TNBC
Partnership with Adlai Nortye in China to develop pelareorep for metastatic breast cancer, as well as additional indications.
Combination study with PD-1 checkpoint inhibitor in
triple-negative breast cancer (TNBC).

We have established international collaborations with leading institutions in the UK, USA and Asia to further expand the application of TNAT-101 across multiple cancer types

As we attract additional investments, we also continue to investigate collaboration and partnership opportunities, particularly with additional immuno-oncology agents, including bispecific antibodies, and CDK4/6 and PARP inhibitors.

OUR HISTORY

The TNA Journey So Far

2013

WORK ON TNA'S FIRST MOLECULE BEGAN

The work on the company's first molecule began 2013. Since this time significant time and investment has gone into testing this molecule to further increase our chance of success.

2015

PATENT FOR FIRST BCL-3 INHIBITOR WAS FILED

2 patent families provide worldwide protection for TNAT-101 and derivatives. With composition of matter granted in a number of territories